BioSpace News Archive

The results showed that six weeks of treatment with LATUDA was associated with statistically significant and clinically meaningful improvement in a wide range of depressive symptoms compared to placebo.

Comments from the CEO: “During the third quarter of 2017, BioInvent has initiated preparations for a clinical trial with BI-1206 in combination with rituximab to investigate its potential as a treatment of relapsing, aggressive forms of Non-Hodgkin Lymphoma and indolent lymphomas.”

Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Irish based Arran Chemical Company has responded to client demand for provision of fine chemicals, pharmaceutical intermediates and advanced building blocks by implementation of its ADAPT (Arran Deploys Advanced Production Technologies) strategy through a multi-million Euro investment and application of its selectAZyme technology.

Galapagos’ financial report for the first three quarters ended 30 September 2017 can be accessed on the company’s website.

The company reported Q3 2017 results, provided guidance, and announced a $0.055/share dividend.

The company announced the receipt of approximately USD$605,263 in gross proceeds from the early exercise of 2,631,579 April 2017 warrants at USD$0.23 (CAD$0.31) per share.

Data from this trial was also presented at the conference yesterday.

Genentech announced today that new OCREVUS (ocrelizumab) data are being presented at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

The study is designed to investigate the immune tolerance induction potential of Elocta in patients with hemophilia A who have developed inhibitors which have failed to be resolved with other therapies.